摘要
目的研究长效干扰素对乙型肝炎E抗原(HBeAg)阳性慢性乙型肝炎(CHB)患者肝功能以及慢性乙型肝炎患者特异性生活质量量表(QLS-CHB)评分的影响。方法42例HBeAg阳性CHB患者为研究对象,以随机数字表法分为观察组和对照组,各21例。对照组使用恩替卡韦分散片治疗,观察组使用聚乙二醇干扰素α-2b注射液治疗。比较两组治疗效果,乙型肝炎病毒脱氧核糖核酸(HBV DNA)、乙型肝炎表面抗原(HBsAg)水平及HBeAg、HBV DNA转阴情况,肝功能指标[血清谷丙转氨酶(ALT)、血清谷草转氨酶(AST)、血清白蛋白(ALB)],生活质量,不良反应发生情况。结果治疗后,观察组治疗总有效率90.48%高于对照组的47.62%,差异有统计学意义(P<0.05)。治疗后,两组HBV DNA、HBsAg水平均低于本组治疗前,且观察组HBV DNA(2.48±0.37)U/ml、HBsAg(56.56±8.59)U/L均低于对照组的(3.55±0.44)U/ml、(98.43±12.87)U/L,差异有统计学意义(P<0.05)。治疗后,观察组HBeAg、HBV DNA转阴率分别为57.14%、85.71%,均高于对照组的23.81%、52.38%,差异有统计学意义(P<0.05)。治疗后,两组ALT、AST水平均低于本组治疗前,ALB水平高于本组治疗前,且观察组ALT(32.94±4.17)U/L、AST(31.15±4.32)U/L均低于对照组的(45.22±5.56)、(44.28±5.46)U/L,ALB(36.92±4.21)g/L高于对照组的(30.55±4.74)g/L,差异有统计学意义(P<0.05)。治疗后,两组症状、生理、心理、社会评分均高于本组治疗前,且观察组高于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论长效干扰素治疗HBeAg阳性CHB患者能够有效降低HBV DNA、HBsAg水平,提高HBeAg、HBV DNA转阴率,改善患者肝功能水平,提升其生活质量,疗效更佳。
Objective To study the effects of long-acting interferon on liver function indexes and quality of life scale for patient with chronic hepatitis B(QLS-CHB)scores in hepatitis B e antigen(HBeAg)-positive chronic hepatitis B(CHB)patients.Methods A total of 42 cases of HBeAg-positive CHB patients were divided into observation group and control group according to the random numerical table,with 21 cases in each group.The control group was treated with entecavir dispersible tablets,and the observation group was treated with peginterferon alfa-2b injection.Both groups were compared in terms of therapeutic effects,the levels of hepatitis B virus deoxyribonucleic acid(HBV DNA),hepatitis B surface antigen(HBsAg),the negative conversion of HBeAg and HBV DNA,the liver function indexes[serum alanine aminotransferase(ALT),serum aspartate transaminase(AST),serum albumin(ALB)],quality of life,and occurrence of adverse reactions.Results After treatment,the total effective rate of 90.48%in the observation group was higher than that of 47.62%in the control group,and the difference was statistically significant(P<0.05).After treatment,HBV DNA and HBsAg levels in both groups were lower than those before treatment in this group;HBV DNA of(2.48±0.37)U/ml and HBsAg of(56.56±8.59)U/L in the observation group were lower than those of(3.55±0.44)U/ml and(98.43±12.87)U/L in the control group;the differences were statistically significant(P<0.05).After treatment,the negative conversion rates of HBeAg and HBV DNA in the observation group were 57.14%and 85.71%,which were higher than those of 23.81%and 52.38%in the control group,and the differences were statistically significant(P<0.05).After treatment,ALT and AST levels in both groups were lower than those before treatment in this group,and ALB level was higher than that before treatment in this group;ALT of(32.94±4.17)U/L and AST of(31.15±4.32)U/L in the observation group were lower than those of(45.22±5.56)and(44.28±5.46)U/L in the control group;ALB of(36.92±4.21)g/L in the observation group was higher than that of(30.55±4.74)g/L in control group;the differences were statistically significant(P<0.05).After treatment,the symptoms,physiological,psychological and social scores in both groups were higher than those before treatment in this group,and the observation group was higher than the control group.The differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Application of long-acting interferon in the treatment of HBeAg-positive CHB patients can effectively reduce HBV DNA and HBsAg levels,increase conversion rate of HBeAg and HBV DNA,improve liver function level,enhance quality of life,and have better efficacy.
作者
安萍
卞丽
AN Ping;BIAN Li(Department of Hepatology,Shenyang Sixth People's Hospital,Shenyang 110006,China)
出处
《中国现代药物应用》
2023年第15期94-97,共4页
Chinese Journal of Modern Drug Application
关键词
乙型肝炎E抗原阳性
慢性乙型肝炎
恩替卡韦
长效干扰素
肝功能
生活质量
Hepatitis B e antigen positive
Chronic hepatitis B
Entecavir
Long-acting interferon
Liver function
Quality of life
